Publication:
Do probiotic interventions improve female unexplained infertility? A critical commentary

dc.contributor.coauthorFavaron, Alessia
dc.contributor.coauthorElbadawi, Moe
dc.contributor.coauthorGaisford, Simon
dc.contributor.coauthorBasit, Abdul W.
dc.contributor.coauthorOrlu, Mine
dc.contributor.kuauthorTürkgeldi, Engin
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.date.accessioned2024-12-29T09:39:34Z
dc.date.issued2024
dc.description.abstractDisruption of women's gut and cervicovaginal microbiota has been associated with multiple gynaecological diseases such as endometriosis, polycystic ovary syndrome, non-cyclic pelvic pain and infertility. Female infertility affects 12.6% of women worldwide;its aetiology is complex and multifactorial and can be underpinned by uterine pathologies, systemic diseases and age. In addition, a new perspective has emerged on the role of the gut and vaginal microbiomes in reproductive health. Research shows that the administration of precisely selected probiotics, often in combination with prior antibiotic treatment, may facilitate the restoration of symbiotic microbiota to increase successful conception and assisted reproductive technology outcomes. However, clarity on this issue from fuller research is currently hampered by a lack of consistency and harmonization in clinical studies: various lactobacilli and bifidobacteria species have been delivered through both the oral and vaginal routes, in different dosages, for different treatment durations. This commentary explores the intricate relationship between the microbiota in the cervicovaginal area and gut of women, exploring their potential contribution to infertility. It highlights ongoing research on the use of probiotic formulations in improving pregnancy outcomes, critically examining the divergent findings in these studies, which complicate a conclusive assessment of the efficacy of these interventions.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue4
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuEU
dc.description.sponsorsAlessia Favaron is supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 956851.
dc.description.volume48
dc.identifier.doi10.1016/j.rbmo.2023.103734
dc.identifier.eissn1472-6491
dc.identifier.issn1472-6483
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85185255596
dc.identifier.urihttps://doi.org/10.1016/j.rbmo.2023.103734
dc.identifier.urihttps://hdl.handle.net/20.500.14288/23053
dc.identifier.wos1186773200001
dc.keywordsFemale reproductive health
dc.keywordsInfertility
dc.keywordsMicrobiome
dc.keywordsMicrobiota
dc.keywordsProbiotic
dc.languageen
dc.publisherElsevier Sci Ltd
dc.relation.grantnoEuropean Union [956851]
dc.relation.grantnoMarie Curie Actions (MSCA) [956851] Funding Source: Marie Curie Actions (MSCA)
dc.sourceReproductive Biomedicine Online
dc.subjectObstetrics and gynecology
dc.subjectReproductive biology
dc.titleDo probiotic interventions improve female unexplained infertility? A critical commentary
dc.typeOther
dc.type.otherNote
dspace.entity.typePublication
local.contributor.kuauthorTürkgeldi, Engin

Files